Vial switch improves life-saving antiviral drug
Legacy Pharmaceuticals uses SCHOTT Type I Plus vials to overcome a leaching issue.
Legacy Pharmaceuticals, a Swiss-based global contract manufacturer of sterile/aseptic pharmaceutical products in ampoules and vials, is collaborating with SCHOTT, a leading company in innovative glass production and technology, to solve a technical challenge. Legacy turned to SCHOTT Type I Plus vials to overcome a leaching issue for a life-saving antiviral drug product. This was successful, and Legacy and SCHOTT are now offering this solution to future customers with a need to provide better stability, particularly for highly sensitive formulations.
Protein adsorption and leaching from primary packaging are known to be root causes of reduced shelf life in many formulations. Ion leaching, especially for sodium, aluminium and other metal ions, forms uncoated type I glass and leads to pH shift and decreased stability or activity of biopharmaceuticals. The SCHOTT Type I Plus vials have an inside SiO2 coating with outstanding barrier properties.
“The barrier layer in the vials comes with multiple benefits: it prevents depletion of the glass container by the drug formulation and also acts as a diffusion barrier for all leachables of the glass matrix, supressing them to a level below their respective detection limit. The diffusion barrier is certified by a release test with a limit for sodium leaching (0.17 mg/l) less then 1/10 of the required sodium level for Type 1 containers (2.4 mg/l),” says Dr Bernhard Hladik, Senior Business Development Manager at SCHOTT.
This reduces the interaction between drug product and container surface, thereby providing a superior packaging solution for sensitive drug products.
“The number of injectable drugs coming to market continues to grow. However, many of the new formulations are highly sensitive. This imposes increasing demands on primary packaging - both vials and stoppers. Drawing on our longstanding expertise and knowledge of APIs and buffer systems, we proactively looked for new solutions to meet our customer’s demands. We have now identified, and validated the SCHOTT Type I Plus vials as a reliable option for our customers,“ commented Mike Danzi, CEO of Legacy Pharmaceuticals.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance